Results 21 to 30 of about 701,268 (244)
Annals of Oncology, 2013 Polychemotherapy and biological drugs have increased therapeutic options and outcomes of advanced colorectal cancer (CRC). We examined the relation between progression-free survival (PFS), post-progression survival (PPS) and overall survival (OS) in trials of modern (oxaliplatin- and irinotecan-based) chemotherapy alone or with targeted therapies for ...
Petrelli, F., Barni, S.
openaire +3 more sources
The Application of Clinical Genetics, 2022 Naglaa S Elabd,1 Shimaa E Soliman,2 Moamena S Elhamouly,1 Suzy F Gohar,3 Ayman Elgamal,4 Mahmoud Magdy Alabassy,5 Haitham A Soliman,5 Abdelnaser A Gadallah,6 Osama D Elbahr,7 Ghada Soliman,3 Amany A Saleh2 1Tropical Medicine Department, Faculty of ...
Elabd NS +10 more
doaj
Frontiers in Nutrition, 2023 BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie +16 more
doaj +1 more source
Acta OncologicaBackground: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of
Aino Rajamaki +10 more
doaj +1 more source
Contemporary Oncology, 2016 We still do not know whether the presently used protocol of the first-line palliative treatment of disseminated colorectal cancer (FOLFOX/FOLFIRI protocol) allows maximization of therapeutic response and minimization of side effects.
Wojciech Rogowski +1 more
doaj +1 more source
Hepatology Research, 2015 AbstractAimAlthough sorafenib is a standard drug for advanced hepatocellular carcinoma (HCC), little is known about a patient's clinical course after treatment. We investigated the effect of post‐progression survival (PPS) and progression‐free survival (PFS) on overall survival (OS) in patients whose advanced HCC was treated by sorafenib.MethodsWe ...
Terashima, Takeshi +11 more
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Central nervous system (CNS) neuroblastoma, FOXR2‐activated, is a recently recognized entity in the WHO CNS5 classification, defined by activation of the FOXR2 transcription factor and unique histopathological features. This review synthesizes available literature and pooled clinical data, providing insight into demographics ...
Sudarshawn Damodharan +1 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier +10 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body.
Charles Nakar +7 more
wiley +1 more source
European Journal of Medical ResearchBackground Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options.
Elyar Mahboubi +3 more
doaj +1 more source